In the last three months, 4 analysts have published ratings on Beam Therapeutics (NASDAQ:BEAM), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.5, along with a high estimate of $57.00 and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 43.42% increase from the previous average price target of $30.33.
Understanding Analyst Ratings: A Comprehensive Breakdown
Login or create a forever free account to read this news
Sign up/Log in